Korro Bio Stock Climbs Before Holiday; Bigger Test Still to Come
Korro Bio shares closed at $11.61 Friday, up 3.66% and about 14% above the May 15 close, before U.S. markets shut for Memorial Day. The company named KRRO-111 as its new AATD drug candidate after an earlier setback, reporting over 90% RNA editing in mouse models. Korro ended Q1 with $157.1 million in cash and a narrower net loss. H.C. Wainwright cut its price target to $15 from $20.